Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013
Brain Metastases
The Neurologist 10:31-46, Klos,K.J.&O'Neill,B.P., 2004
Infiltration of the Leptomeninges by Systemic Cancer:a Clinical & Pathologic Study
Arch Neurol 30:122, Olson,M.E.,et al, 1974
Primary Diffuse Leptomeningeal Melanocytosis, A Diagnoatic Conundrum
Neurol 101:e576-3580, Selvarajan,J.M.P.,et al, 2023
Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors in Patients with Melanoma
Neurol 101:e2472-e2482, Pepys,J.,et al, 2023
In Patients with Melanoma Brain Metastases, is Combination Immune Checkpoint Inhibition a Safe and Effective First-Line Treatment? A Critically Appraised Topic
Neurologist 27:290-297, Gritsch, D.,et al, 2022
Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Association of Innovations in Radiotherapy and Systemic Treatments with Clinical Outcomes in Patients with Melanoma Brain Metastasis From 2007 to 2016
JAMA doi:10.1001/JAMANETWORKOPEN.2020.8204, Brastianos, H.C.,et al, 2020
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
NEJM 379:722-730,789, Tawbi, H.A.,et al, 2018
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Inflammatory Demyelinating Polyneuropathy Versus Leptomeningeal Disease Following Ipilimumab
J Immunother Cancer 6:11, Cafuir, L.,et al, 2018
Five Cases of Malignant Melanoma During Fingolimod Treatment in Dutch Patients with MS
Neurol 89:970-972, Killestein, J.,et al, 2017
Neurocutaneous Melanosis with Diffuse Leptomeningeal Malignant Melanoma in an Adult
Neurol 86:e75-e79, Bhatia, R.,et al, 2016
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Intracerebral and Subarachnoid Hemorrhage in Patients with Cancer
Neurol 74:494-501, Navi,B.B.,et al, 2010
Natalizumab: A Double-Edged Sword?
Ann Neurol 66:262-263, DeAngelis,L., 2009
Melanoma Complicating Treatment with Natalizumab for Multiple Sclerosis
NEJM 358:647-648, Mullen,J.T.,et al, 2008
Treatment of Brain Metastases of Malignant Melanoma with Temozolomide
NEJM 345:621-622, Biasco,G.,et al, 2001
Neurology and the Skin
JNNP 66:417-430, Hurko,O.&Provost,T.T., 1999
Imaging Features of Intraventricular Melanoma
AJNR 20:691-693, Arbelaez,A.,et al, 1999
Occurrence of Different Cancers in Patients with Parkinson's Disease
BMJ 310:1500-1501, Moller,H.,et al, 1995
Levodopa, Melanoma, and Parkinson's Disease
Neurol 43:674-677, Weiner,W.J.,et al, 1993
Development of Malignant Melanoma after Levodopa Therapy for Parkinson's Disease, Report of Case & Review
Am J Med 79:119-121, Kochar,A.S., 1985
Levodopa & Melanoma:Three Cases & Review of Literature
JNNP 48:585-588, Rampen,F.H.J., 1985
Malignant Melanoma and Central Nervous System Metastases, Incidence, Diagnosis, Treatment and Survival
Cancer 42:660-668, Amer,M.H.,et al, 1978